Abstract
Background: Current mammographic technology has resulted in increased detection of ductal carcinoma in situ (DCIS). It is necessary to assess which patients presenting with DCIS are good candidates for breast conservation and which of these patients should receive adjuvant radiation.
Methods: We accrued clinical data for 124 patients with a primary diagnosis of DCIS from 1979 through 1994. Primary therapy was a mastectomy for 18 patients, and a lumpectomy for 106 patients. Only 18 of the latter group of patients received adjuvant radiotherapy. For the 88 lumpectomy-alone patients (median follow-up, 5.2 years), we evaluated the effects of clinical (age and initial presentation) and pathologic (nuclear grade, architecture, parenchymal involvement, calcifications, and measured margins) factors on recurrence of DCIS or the development of invasive breast cancer.
Results: Patients who underwent lumpectomy with or without adjuvant radiotherapy (median follow-up, 5.0 years) were significantly more likely to have recurrence of DCIS (P=.05) than those who underwent mastectomy (median follow-up, 6.7 years): 18% (19/106) versus 0% (0/18), respectively; lumpectomy-alone patients experienced a 19% (17/88) rate of DCIS recurrence. All recurrent DCIS was ipsilateral. For lumpectomy-alone patients, the factors associated with ipsilateral recurrence of DCIS were extent of involvement of the parenchyma (P=.01, for univariate;P=.07, for multivariate) and initial presentation (P=.05, for univariate;P=.07, for multivariate). Eleven lumpectomy-alone patients developed invasive breast cancer (6 ipsilateral, 5 contralateral); none of the 18 lumpectomy patients who received adjuvant radiation developed invasive disease. None of the factors investigated, including primary surgery and adjuvant radiotherapy, were associated with a significant effect on the development of invasive disease.
Conclusions: Longer follow-up is required to determine if the benefits of either mastectomy or radiotherapy following lumpectomy persist. There is a suggestion that patients under 40 years of age or women who present with nipple discharge might be considered for either adjuvant radiotherapy following lumpectomy or a simple mastectomy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Smigel K. Breast cancer death rates decline for white women.J Natl Cancer Inst 1995;87:173.
Garfinkel L, Boring C, Heath C. Changing trends. An overview of breast cancer incidence and mortality.Cancer 1994;74:222–7.
Silverstein MJ. Incidence and treatment of ductal carcinoma in situ of the breast.Eur J Cancer 1997;33:10–11.
Berardo MD, Hilsenbeck SG, Prosser J, Allred DC. Histological grading of ductal carcinoma in situ (DCIS) (abstract).Breast Cancer Res Treat 1996;41:221.
Fechner RE. One century of mammary carcinoma in situ: what have we learned?Am J Clin Pathol 1993;100:654–61.
Chapman JW, Wolman E, Wolman SR, et al. Assessing genetic markers of tumour progression in the context of intra-tumour heterogeneity.Cytometry 1998;31:67–73.
Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification: a study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.Semin Diagn Pathol 1994;11:208–14.
Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.N Engl J Med 1993;328:1581–6.
Chapman JW, Murray D, McCready DR, et al. An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer?Eur J Cancer 1996;32A:1949–56.
Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence.Cancer 1989;63:618–24.
Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization.Hum Pathol 1993;24:16–23.
Chapman JW, Hanna W, Kahn HJ, Lickley HLA, Wall J, Fish EB, McCready DR. Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone.Surg Oncol 1996;5:265–71.
Lagios MD. Heterogeneity of ductal carcinoma in situ of the breast.J Cell Biochem 1993;17G(suppl):49–52.
van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A. Ductal carcinoma in-situ of the breast: second EORTC consensus meeting.Eur J Cancer 1992;28:626–9.
Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17.Cancer 1995;75:1310–9.
Fisher ER, Sass R, Fisher B, Wickerman L, Pail SM, and Collaborating NSABP Investigators. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6) 1. Intraductal Carcinoma (DCIS).Cancer 1986;57:197–208.
Eusebi V, Feudale E, Foschini M, et al. Long-term follow-up of in situ carcinoma of the breast.Semin Diagn Pathol 1994;11:223–35.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fish, E.B., Chapman, JA.W., Miller, N.A. et al. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast. Annals of Surgical Oncology 5, 724–732 (1998). https://doi.org/10.1007/BF02303484
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02303484